Clinical trial
Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
NCT04698850 is registered in ClinicalTrials.gov with Faculty Hospital Kralovske Vinohrady as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
- Lead sponsor
- Faculty Hospital Kralovske Vinohrady
- Phase
- Phase 4
- Overall status
- Withdrawn
- Start date
- January 4, 2021
- Completion date
- June 30, 2023
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.